PAVmed Inc. (PAVM) revealed Third Quarter 2020 Financial Results and Business Update

The Company and its subsidiaries Lucid Diagnostics and Solys Diagnostics received a Business Update from PAVmed Inc. (Nasdaq: PAVM) and addressed the details of financial operations for 3 and 9 months ended 30 September 2020.

Research and development expenditures for 3 months ended 30 September 2020 amounted to $2.6 million, with general and administrative costs in line with the previous period of $2.9 million. GAAP net loss of $5.6 million or $(0.11), per common share attributable to common stockholders.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The Corporation announced non-GAAP adjusted losses of $4.5 million for the three months ended September 30, 2020, or $(0.09) of the common share to assist readers in recognizing the impact of the derivative and other non-cash revenue and expenditures on the Company’s financial performance.

As of 30 September 2020, PAvmed had $8.3 million in currency and cash equivalents, compared to $6.2 million in 2019, compared to 31 December.

The quarter ending includes $448 of stock-based compensation expense given as general and administrative expenses and $138 posted as R&D expense.

For the period $269 is reported as general and administrative costs for inventory-based salaries and $61 is reported as research and development spending.

The reported quarter comprises $1.132 in the overall and operating costs incurred on stock-based compensation and $326 in the expenditures reported on research and growth.

A highly differentiated, multi-product, healthcare device firm closed 1.66% down to 1.78, yesterday’s volume was recorded 482.2K against the company’s average volume of 562.34K. the firm with a Market Capitalization of 93.56K is trading -4.47% away from its 50 days Simple Moving Average.

Most Popular

Related posts